Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
alfaxalone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 133 | 23930-19-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 2.03 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,EIF2AK3,EPHB4,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK,TGFBR1 | 21 | |||
| kinase-selectivity-class | EIF2AK3 | 1 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1972 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N01AX05 | NERVOUS SYSTEM ANESTHETICS ANESTHETICS, GENERAL Other general anesthetics |
| MeSH PA | D000081227 | Neurosteroids |
| MeSH PA | D000777 | Anesthetics |
| MeSH PA | D002491 | Central Nervous System Agents |
| MeSH PA | D002492 | Central Nervous System Depressants |
| MeSH PA | D018377 | Neurotransmitter Agents |
Related Drugs by ATC class:
N01AX Other general anesthetics 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Induction and maintenance of general anesthesia | Indication |
| Cats | Anesthesia followed by maintenance with an inhalant anesthetic | Indication |
| Dogs | Induction and maintenance of general anesthesia | Indication |
| Dogs | Anesthesia followed by maintenance with an inhalant anesthetic | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Alfaxan Multidose | Jurox Pty. Ltd. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium- and chloride-dependent GABA transporter 1 | Transporter | WOMBAT-PK | |||||||
| GABA-A receptor alpha-1/beta-2/gamma-2 | Ion channel | EC50 | 5.70 | WOMBAT-PK | |||||
| GABA A receptor alpha-2/beta-2/gamma-2 | Ion channel | EC50 | 5.70 | CHEMBL | |||||
| GABA-A receptor; anion channel | Ion channel | IC50 | 6.52 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D07282 | KEGG_DRUG |
| 1544577 | RXNORM |
| C0051482 | UMLSCUI |
| CHEBI:34531 | CHEBI |
| EY4 | PDB_CHEM_ID |
| CHEMBL190279 | ChEMBL_ID |
| DB11371 | DRUGBANK_ID |
| C006477 | MESH_SUPPLEMENTAL_RECORD_UI |
| 3218 | INN_ID |
| BD07M97B2A | UNII |
| 104845 | PUBCHEM_CID |
| 5461 | IUPHAR_LIGAND_ID |
| 116553001 | SNOMEDCT_US |
| 387037009 | SNOMEDCT_US |
| BD07M97B2A | INXIGHT DRUGS |
Pharmaceutical products:
None